# Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer

> **NCT07570368** · NA · NOT_YET_RECRUITING · sponsor: **Universitas Airlangga** · enrollment: 54 (estimated)

## Conditions studied

- Breast Cancer
- Breast Neoplasm Female
- Locally Advanced Breast Cancer (LABC)
- Locally Advanced Breast Cancer

## Interventions

- **BEHAVIORAL:** Brief Acceptance and Commitment Therapy
- **BEHAVIORAL:** Standard Counseling
- **DRUG:** Neoadjuvant Chemotherapy

## Key facts

- **NCT ID:** NCT07570368
- **Lead sponsor:** Universitas Airlangga
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-28
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570368, "Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07570368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*